Charles Strongo, CEO of Global WholeHealth Partners Corp (OTC: GWHP) shows his reaction regarding the statement by the incoming director of the Centers for Disease Control. The incoming director warned on January 6 about the death toll reaching 50000 by the mid of February. Mr.Strongo said that the figure by CDC officials was staggering and we should keep increasing testing, wear masks and follow the other rules set by the CDC to stop spreading the Coronavirus.
As the pandemic has increased and still not coming under control, the market related to it is also growing and it has increased the demand for a rapid testing system across the world. People looking for a rapid testing kit that allows detecting the virus quickly. People expecting a population-wide testing approach. Another factor that is affecting the market is the shift from symptomatic testing to mass testing in developed countries
GWHP and its partners know that there is a crucial need for a faster testing kit that provide quick results to fight against the deadly Coronavirus. The GWHP knows that more quick results can stop the spreading of the Coronavirus.GWHP kit is the only FDA authorized COVID-19 POC serology Point of Care Test. It’s a new fingerstick test that makes it easy for health workers to test the patient just by pricking a patient’s finger and get results in minutes without having to wait for venous blood. With the new testing kits, GWHP will be able to distribute these tests to more urgent cares, to stop the spread of the Coronavirus.
The Health authorities are expecting a third wave of the Corona virus and experts across the country saying that still aren’t enough tests available to control the virus from spreading.According to the surveys, the USA required 193 million tests a month to control the virus but at the moment only 30 million Covid-19 tests are done every month. Authorities have the fear that the next wave of the Corona virus will be worse than the previous one and GWHP said that they are confident that their new rapid testing kit will make a difference and will help control the Coronavirus.
The new rapid kit provides cutting-edge technology using In-vitro Diagnostic (IVD) Real-Time PCR Machines for detection of SARS-CoV-2 IgM/IgG antibodies in human serum, plasma, or whole blood. Global’s Antibody test can detect the new CoViD 19 SARS 2 strains and detect if the vaccine was able to produce the antibody IgG in the recipient of the vaccine. The Company can deliver hundreds of thousands of new test kits, up to 1 million per day.